Spruce Biosciences, Inc.

NasdaqCM:SPRB Stock Report

Market Cap: US$83.0m

Spruce Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:SPRB Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
07 Oct 25SellUS$2,574,875Odlander, Fredrikson & Co. ABCompany12,500US$205.99
06 Oct 25BuyUS$4,585Parkman Healthcare Partners LLCCompany256US$17.91
06 Oct 25SellUS$4,920Parkman Healthcare Partners LLCCompany257US$19.33

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SPRB?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders98,8529.24%
Institutions157,36014.7%
Hedge Funds301,00528.1%
General Public513,15347.9%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 94.4%.

Top Shareholders

Top 21 shareholders own 52.06% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.3%
Ikarian Capital, LLC
121,356US$9.4m810%1.61%
10.2%
Citadel Advisors LLC
109,649US$8.5m0%0.01%
6.54%
Squadron Capital Management Llc
70,000US$5.4m0%no data
6.37%
Peter Boone
68,184US$5.3m0%no data
3.61%
Abingworth LLP
38,620US$3.0m0%4.61%
2.7%
Armistice Capital LLC
28,923US$2.2m0%0.06%
2.54%
Odlander, Fredrikson & Co. AB
27,201US$2.1m-31.5%2.01%
2.49%
Cable Car Capital LLC
26,666US$2.1m0%1.42%
1.78%
Javier Szwarcberg
19,004US$1.5m205%no data
1.67%
The Vanguard Group, Inc.
17,873US$1.4m0%no data
1.46%
RiverVest Venture Management LLC
15,580US$1.2m0%69.99%
0.77%
Samir Gharib
8,263US$640.8k76.8%no data
0.2%
Ralph Charlton
2,151US$166.8k0%no data
0.12%
Kirk Ways
1,250US$96.9k0%no data
0.098%
Parkman Healthcare Partners LLC
1,050US$81.4k0%0.01%
0.093%
Lion Point Capital, LP
1,000US$77.6k0%0.36%
0.019%
Sound Income Strategies, LLC
200US$15.5k0%no data
0.012%
Osaic Wealth, Inc.
133US$10.3k0%no data
0.0092%
Morgan Stanley
98US$7.6k0%no data
0.0012%
Caldwell Sutter Capital, Inc.
13US$1.0k0%no data
0.00028%
Bank of America Corporation
3US$232.40%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/02 23:09
End of Day Share Price 2026/02/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Spruce Biosciences, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aydin HuseynovBenchmark Company
Jonathan WollebenCitizens JMP Securities, LLC
Raghuram SelvarajuH.C. Wainwright & Co.